Literature DB >> 18654781

A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.

Adrian Tempescul, Johanna Feuerbach, Jean-Christophe Ianotto, Florence Dalbies, Veronique Marion, Marie-Josée Le Bris, Marc De Braekeleer, Christian Berthou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18654781     DOI： 10.1007/s00277-008-0541-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

Review 1.  Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.

Authors:  Aude Collignon; Anne Wanquet; Elsa Maitre; Edouard Cornet; Xavier Troussard; Thérèse Aurran-Schleinitz
Journal:  Curr Oncol Rep       Date:  2017-04       Impact factor: 5.075

2.  Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.

Authors:  H Coelho; M Badior; T Melo
Journal:  Case Rep Hematol       Date:  2017-07-27

3.  Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax.

Authors:  Maria Tariq Siddiqui; Allyson Price; Alessandra Ferrajoli; Gautam Borthakur
Journal:  Leuk Res Rep       Date:  2021-08-30

4.  A Novel Treatment With Obinutuzumab-Chlorambucil in a Patient With B-Cell Prolymphocytic Leukemia: A Case Report and Review of the Literature.

Authors:  Jason Hew; Dat Pham; Trevanne Matthews Hew; Vinay Minocha
Journal:  J Investig Med High Impact Case Rep       Date:  2018-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.